Questions

1. Varicella Vaccine Dosing Intervals:
   • Aged 12 months to 12 years: Administer dose 1 at 12–15 months. The second dose is preferably administered 3 to 6 months after the first dose (absolute minimum interval: 3 months).
   • Aged ≥12 years: Administer 2 doses with a minimum interval of 4 weeks (preferably 4 to 8 weeks).
2. Quadrivalent Meningococcal Conjugate Vaccine (MenACWY):
   • Menactra (MenACWY-DT): Approved as a 2-dose primary series between 9 and 23 months of age, administered at least 3 months apart (or single dose if given at ≥2 years of age).
   • MenQuadfi (MenACWY-TT) / Nimenrix (MenACWY-TT): Nimenrix can be administered from 6 weeks of age (2 doses 2 months apart plus a booster at 12 months, or single dose if initiated ≥12 months). MenQuadfi is licensed as a single dose from 12 months of age onwards.
3. Hepatitis A Vaccine Schedules:
   • Live Attenuated Vaccine (H2 strain): Single subcutaneous dose at 12 months of age or older. No booster dose is routinely required.
   • Inactivated Hepatitis A Vaccine: 2-dose schedule given intramuscularly at 12 months of age or older, separated by an interval of 6 months (dose 1 at 12 months, dose 2 at 18 months).
4. Pneumococcal Conjugate Vaccine (PCV) Schedule:
   • Standard 3 + 1 Schedule: 3 primary doses administered at 6, 10, and 14 weeks of age (minimum interval 4 weeks; starting no earlier than 6 weeks).
   • Booster Dose: Single booster administered at 12 to 15 months of age (minimum 6 months after the third primary dose).
   • Alternative 2 + 1 Schedule: Permissible at 6 and 14 weeks (or 2 and 4 months) followed by a booster at 12–15 months.

1. Core Recommended Adolescent Vaccines (10–12 Years):
   • Tetanus, reduced diphtheria, and acellular pertussis vaccine (Tdap).
   • Human Papillomavirus vaccine (HPV).
   • Catch-up Measles-Mumps-Rubella (MMR) vaccine (if 2 doses not documented).
   • Catch-up Varicella and Hepatitis B vaccines (if unvaccinated).
2. Human Papillomavirus (HPV) Vaccination:
   • Age 9 to 14 years (Patient is 12 years): 2-dose schedule administered at 0 and 6 months (minimum interval 5 months; if dose 2 is given earlier than 5 months, a third dose is mandatory at least 6 months after dose 1).
   • Age ≥15 years or Immunocompromised: 3-dose schedule administered at 0, 1–2, and 6 months (minimum intervals: 4 weeks between dose 1 and 2; 12 weeks between dose 2 and 3; 5 months between dose 1 and 3).
   • Route and Site: 0.5 mL Intramuscularly (IM) in the deltoid muscle.
3. Tetanus and Diphtheria Protection (Tdap / Td):
   • Administer 1 dose of Tdap at 10–12 years of age (preferred over Td to boost pertussis immunity).
   • Follow with a booster dose of Td (or Tdap) every 10 years throughout life.
4. Catch-up Immunizations to Review:
   • MMR: If only 1 or 2 doses of MR/measles were received in infancy, administer catch-up MMR (1 or 2 doses, minimum 4 weeks apart).
   • Varicella: If uninfected and unimmunized, 2 doses administered at least 4 to 8 weeks apart (since age ≥12 years).
   • Hepatitis B: If unimmunized, 3-dose catch-up series at 0, 1, and 6 months.
   • Hepatitis A: If unimmunized, 2 doses of inactivated vaccine (0 and 6 months) or single dose of live attenuated vaccine.
   • Typhoid: Single dose of Typhoid Conjugate Vaccine (TCV) if not received previously.

1. AEFI Categorization:
   • Presentation A: Vaccine product-related reaction (inherent pharmacological property of whole-cell pertussis endotoxin and aluminium adjuvant).
   • Presentation B: Vaccine quality defect-related reaction (manufacturing defect in viral inactivation).
   • Presentation C: Immunization error-related reaction (programmatic error: incorrect route/technique of administration).
   • Presentation D: Immunization error-related reaction (programmatic error: contamination due to needle/syringe reuse).
   • Presentation E: Immunization anxiety-related reaction (stress response to the injection procedure).
2. Serious vs. Severe AEFI:
   • Serious AEFI: An event that is regulatory/outcome-defined: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or causes a congenital anomaly/birth defect.
   • Severe AEFI: A clinical severity grading indicating high intensity of symptoms (e.g., high-grade fever >39°C, large local swelling) that does not necessarily meet the criteria for a "serious" event (most severe AEFIs resolve completely without sequelae or hospitalization).
3. Emergency Management of Anaphylaxis in an 8 kg Infant:
   • First-line Drug: Adrenaline (Epinephrine) 1:1000 ($1\text{ mg/mL}$).
   • Route and Site: Intramuscular (IM) injection into the anterolateral aspect of the middle third of the thigh.
   • Weight-based Dose: $0.01\text{ mg/kg}$ of 1:1000 solution ($0.01\text{ mL/kg}$).
   • Calculated Dose for 8 kg:
     $$ > \begin{aligned} > \text{Dose} &= 8\text{ kg} \times 0.01\text{ mL/kg} \\ > &= \mathbf{0.08\text{ mL}} \quad (\text{maximum single infant dose: } 0.1\text{ to } 0.3\text{ mL}) > \end{aligned} > $$
   • Repeat every 5 to 15 minutes as needed based on hemodynamic and airway response (maximum 3 doses).
4. National Reporting Protocol:
   • Timeline: Serious AEFI must be reported within 24 hours of occurrence/notification.
   • Form: Preliminary Case Reporting Form (CRF) / First Information Report (FIR).

1. Etiologies for Absence of BCG Scar:
   • Normal biological variation / Scar fading: Up to 10% to 15% of immunocompetent, successfully vaccinated infants fail to develop a visible scar or the scar regresses over time.
   • Faulty injection technique: Subcutaneous deposition rather than correct intradermal injection.
   • Cold chain breach / Inactivated vaccine: Exposure of reconstituted vaccine to heat, direct sunlight, or use beyond 4 hours of reconstitution resulting in non-viable bacilli.
   • Inadequate dose delivery: Leakage or partial dose delivery during administration.
2. Recommendation Regarding Re-vaccination:
   • Do NOT re-vaccinate.
   • Rationale: Tuberculin skin test (TST) conversion and cell-mediated immunity against severe forms of tuberculosis (miliary tuberculosis and tuberculous meningitis) develop equally in scar-positive and scar-negative vaccinated infants. Repeat vaccination confers no documented additional clinical protection and increases the risk of local reactogenicity and ulceration.
3. Morphological Evolution of BCG Lesion:
   • Immediate (0–30 minutes): Raised, pale, circumscribed wheal with pitted ("peau d'orange") appearance that resolves within hours.
   • 2 to 3 weeks: Erythematous papule or nodule develops at the injection site.
   • 5 to 6 weeks: Papule enlarges, softens, and ulcerates with slight serous/purulent discharge.
   • 8 to 12 weeks: Ulcer spontaneously dries, crusts, and heals by scarring, leaving a permanent round, slightly depressed, punctate scar (typically 4–8 mm in diameter).
4. Complications and Management:
   • Complications: Non-suppurative regional lymphadenitis (axillary/cervical), suppurative lymphadenitis, injection-site sterile abscess, lupus vulgaris, BCG osteomyelitis, disseminated BCGosis (in primary immunodeficiency).
   • Management of Isolated Non-suppurative BCG Lymphadenitis: Reassurance and watchful waiting; no systemic anti-tubercular therapy (ATT) and no surgical excision/incision. Most cases resolve spontaneously within 2 to 6 months.

1. Biomedical Waste Segregation Protocol:
   • Article 1 (Cut metallic needles): White Translucent Puncture-proof, Tamper-proof Container (PPC).
   • Article 2 (Cut plastic syringe barrels/plungers): Red non-chlorinated plastic bag / container (designated for recyclable contaminated plastics).
   • Article 3 (Intact empty glass vials): Blue cardboard box / container (or puncture-proof leak-proof blue container designated for glassware).
   • Article 4 (Broken glass ampoules): Blue cardboard box / container or designated puncture-proof glass container.
   • Article 5 (Syringe wrappers and outer packaging): Black / Green municipal bin (General non-biomedical / non-infectious dry waste).
   • Article 6 (Blood-soiled cotton swabs): Yellow non-chlorinated plastic bag (incinerable anatomical/soiled absorbent waste).
2. Sharps Disinfection Protocol:
   • Disinfectant: Sodium hypochlorite solution.
   • Concentration: 1% to 2% available chlorine (10,000 to 20,000 ppm).
   • Minimum Contact Time: 30 minutes.
3. Rationale for Needle Hub Cutter at Point of Care:
   • Immediately severs the metal needle from the plastic hub, permanently disabling the syringe to prevent syringe reuse and illicit repackaging.
   • Eliminates needle recapping, thereby reducing accidental needle-stick injuries (NSI) and occupational transmission of blood-borne pathogens (HBV, HCV, HIV).
4. Maximum Permissible Storage Time:
   • Untreated biomedical waste must not be stored beyond 48 hours without prior authorization from the designated state pollution control board.

1. Immediate and Subsequent Catch-up Plan for a 5-Year-Old Child:
   • Visit 1 (Day 0 / Immediate):
     • DTaP (or wP-containing combination) + IPV (dose 1, IM)
     • Hepatitis B (HepB-1, IM)
     • MMR (MMR-1, SC)
     • Varicella (Varicella-1, SC)
     • Typhoid Conjugate Vaccine (TCV, single dose, IM)
     • Hepatitis A (Live attenuated single dose SC, or Inactivated HepA-1 IM)
     • Pneumococcal Conjugate Vaccine (PCV-1, IM; single dose of PCV13/15/20 is recommended between 24 and 59 months)
     • Note on BCG: Catch-up BCG is recommended only up to 5 years (60 months) of age; since he has reached 5 years and has no scar, BCG is generally not offered beyond 5 years under standard national guidelines unless Mantoux testing is non-reactive and clinical policy mandates it.
   • Visit 2 (4 Weeks / 1 Month after Visit 1):
     • DTaP/wP + IPV (dose 2, IM)
     • HepB (dose 2, IM)
     • MMR (dose 2, SC)
   • Visit 3 (8 Weeks / 2 Months after Visit 1):
     • DTaP/wP + IPV (dose 3, IM)
   • Visit 4 (6 Months after Visit 1):
     • HepB (dose 3, IM; minimum 16 weeks after dose 1 and 8 weeks after dose 2)
     • Varicella (dose 2, SC; minimum interval 3 months in children <13 years)
     • Inactivated HepA (dose 2, IM; if inactivated vaccine was used at Visit 1)
   • Booster Dose:
     • DTaP + IPV booster at 4 to 5 years after primary catch-up series, or prior to school entry.
2. Upper Age Limits for Catch-Up Vaccines:
   • BCG: Up to 5 years (60 months) of age (under UIP, up to 1 year; under IAP, up to 5 years).
   • Haemophilus influenzae type b (Hib): Up to 59 months (4 years 364 days). Not recommended for healthy immunocompetent children ≥5 years.
   • Rotavirus Vaccine:
     • Maximum age for first dose: 14 weeks and 6 days (15 weeks).
     • Maximum age for last dose: 8 months 0 days (32 weeks). Catch-up beyond 8 months is strictly contraindicated.
   • Pneumococcal Conjugate Vaccine (PCV): Up to 59 months (4 years 364 days) in healthy children. Catch-up beyond 5 years is indicated only in high-risk conditions (e.g., sickle cell disease, asplenia, HIV, cochlear implants).
3. Pertussis and Tetanus Catch-Up Protocol for Children ≥7 Years:
   • Children aged ≥7 years must not receive pediatric DTwP or DTaP due to increased reactogenicity to full-dose diphtheria and pertussis components.
   • Regimen (3-dose primary series):
     • Dose 1 (0 Month): Tdap (reduced-antigen diphtheria, tetanus, and acellular pertussis).
     • Dose 2 (1–2 Months later): Td (Tetanus-diphtheria toxoid).
     • Dose 3 (6 Months after Dose 1): Td.
   • Subsequent booster: Td/Tdap every 10 years.
4. Minimum Interval Rules:
   • Inactivated Vaccines: Minimum interval between primary doses is 4 weeks (28 days). Doses administered ≤4 days before the minimum interval are considered valid; doses given earlier must be repeated.
   • Live Parenteral Vaccines (e.g., MMR, Varicella, Yellow Fever):
     • Must be administered simultaneously (at separate anatomical sites) OR separated by a minimum of 4 weeks (28 days) to avoid immune interference from interferon release.
     • Oral live vaccines (OPV, Rotavirus) have no interval restrictions relative to live injectable vaccines.

graph TD
    A[Unimmunized Child ≥7 Years] --> B[Visit 0: Tdap + IPV-1 + HepB-1 + MMR-1]
    B --> C[4 Weeks Later: Td + IPV-2 + HepB-2 + MMR-2]
    C --> D[6 Months after Visit 0: Td + IPV-3 + HepB-3 + Varicella-2]
    D --> E[Subsequent Boosters: Td or Tdap every 10 years]

Key Principles of Catch-Up Vaccination (IAP ACVIP):

• Lapsed Schedules: A vaccine series never needs to be restarted regardless of the elapsed interval between doses ("doses count, not intervals").
• Simultaneous Administration: Any number of vaccines can be administered in a single visit at distinct anatomical sites (at least 2.5 cm apart) using separate syringes.

1. Bacterial Strains Included in Current Oral Cholera Vaccines:
   • Vibrio cholerae O1:
     • Serotypes: Inaba and Ogawa.
     • Biotypes: Classical and El Tor (heat-killed and formalin-killed whole cells).
   • Vibrio cholerae O139 (Bengal strain, included in bivalent OCVs such as Shanchol and Euvichol/Euvichol-Plus).
   • Dukoral contains V. cholerae O1 (Inaba and Ogawa, classical and El Tor) plus recombinant cholera toxin B subunit (rCTB); it does not contain O139.
2. WHO-Prequalified OCVs and Schedules:
   • Euvichol-Plus / Euvichol / Shanchol (Bivalent killed whole-cell OCV):
     • Eligible age: ≥1 year.
     • Regimen: 2 oral doses administered 14 days apart (minimum interval 2 weeks).
     • Dose: Liquid formulation (entire single-dose vial/tube administered orally without buffer).
   • Dukoral (Monovalent O1 + rCTB):
     • Eligible age: ≥2 years.
     • Children aged 2–5 years: 3 doses separated by 1–6 weeks (administered with sodium bicarbonate buffer).
     • Children ≥6 years and adults: 2 doses separated by 1–6 weeks (with buffer).
3. Diagnostic Investigations:
   • Rapid Diagnostic Test (Field Surveillance): Crystal VC dipstick rapid test (immunochromatographic assay detecting O1 and O139 lipopolysaccharide antigens).
   • Gold-Standard Confirmatory Investigation: Stool culture on selective media—Thiosulfate Citrate Bile Salts Sucrose (TCBS) agar, yielding characteristic large, smooth, yellow colonies; followed by slide agglutination with polyvalent O1/O139 antisera.
4. Resuscitation and Antibiotic Therapy:
   • WHO Fluid Plan C for Severe Dehydration (Age ≥1 year):
     • Fluid of choice: Ringer's Lactate (or Hartmann's solution); total volume = $100\text{ mL/kg} = 18 \times 100 = \mathbf{1800\text{ mL}}$.
     • Phase 1 (First 30 minutes): $30\text{ mL/kg} = 30 \times 18 = \mathbf{540\text{ mL}}$ IV over 30 minutes.
     • Phase 2 (Next 2.5 hours): $70\text{ mL/kg} = 70 \times 18 = \mathbf{1260\text{ mL}}$ IV over $2.5\text{ hours}$ ($504\text{ mL/hr}$).
   • First-Line Antimicrobial Therapy:
     • Azithromycin: $20\text{ mg/kg}$ orally as a single dose ($18 \times 20 = \mathbf{360\text{ mg}}$ PO single dose).
     • Alternative (if susceptible): Doxycycline $2–4\text{ mg/kg}$ PO single dose (or Ciprofloxacin $20\text{ mg/kg}$ PO single dose).

• Contraindications to OCVs:
  • Severe hypersensitivity to any vaccine component.
  • Age <1 year (for Shanchol/Euvichol) or <2 years (for Dukoral).
  • Severe acute febrile illness or acute gastroenteritis (temporary deferral until recovered).
• Vaccine Efficacy: Protection is approximately 65–85% for up to 3–5 years following a complete 2-dose series in individuals aged >5 years, with lower durability in young children (<5 years), warranting booster doses at 2–3 years in endemic zones.

1. Classification of Vaccine Platforms with Examples:
   • mRNA Platform: BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna). Uses lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA encoding the SARS-CoV-2 spike glycoprotein.
   • Recombinant Protein Subunit Platform: Corbevax (receptor-binding domain [RBD] protein subunit formulated with CpG 1018 and alum adjuvants), Novavax / Covovax (full-length recombinant spike nanoparticle with Matrix-M adjuvant).
   • Inactivated Whole-Virion Platform: Covaxin (BBV152, beta-propiolactone-inactivated whole virion with Algel-IMDG adjuvant), CoronaVac (Sinovac).
   • Plasmid DNA Platform: ZyCoV-D (needle-free intradermal needle-free jet delivery system encoding spike protein).
   • Non-Replicating Viral Vector Platform: ChAdOx1 nCoV-19 / Covishield (Chimpanzee adenovirus vector), Ad26.COV2.S (Human adenovirus 26).
2. Pediatric Dosing Schedules and Routes:
   • Corbevax:
     • Age eligibility: Approved in India for children aged 5 to 12 years and 12 to 14 years.
     • Dose & Route: $0.5\text{ mL}$ intramuscularly (deltoid).
     • Schedule: 2 doses administered 28 days apart.
   • Covaxin (BBV152):
     • Age eligibility: Approved in India for children aged 12 to 18 years (and restricted emergency approval for 6–12 years).
     • Dose & Route: $0.5\text{ mL}$ intramuscularly.
     • Schedule: 2 doses administered 28 days apart.
   • BNT162b2 (Pfizer-BioNTech):
     • 6 months to 4 years: 3-dose primary series ($3\ \mu\text{g}/0.2\text{ mL}$ per dose; dose 1 and 2 separated by 3 weeks, dose 3 at least 8 weeks after dose 2).
     • 5 to 11 years: 2-dose series ($10\ \mu\text{g}/0.2\text{ mL}$ per dose, 3 weeks apart).
     • ≥12 years: 2-dose series ($30\ \mu\text{g}/0.3\text{ mL}$ per dose, 3 to 8 weeks apart).
     • Route: Intramuscular.
3. mRNA Vaccine-Associated Myocarditis/Pericarditis:
   • Pathophysiology: Rare, self-limiting hyper-inflammatory myocardial response mediated by molecular mimicry between spike antibody and self-antigens, natural killer cell activation, and circulating unbound free spike protein escaping clearance. Highest incidence in male adolescents/young adults (12–29 years) typically 2 to 4 days after the second dose.
   • CDC/Brighton Collaboration Case Definition Criteria (Probable/Confirmed):
     • Clinical symptoms: Acute chest pain, dyspnea, or palpitations.
     • Biomarkers: Elevated cardiac troponin (Troponin I or T) above upper reference limit.
     • Electrocardiogram (ECG): ST-segment elevations, PR depressions, or arrhythmias.
     • Imaging confirmation: Echocardiography showing regional wall motion abnormalities or decreased ejection fraction; or Cardiac MRI showing Lake Louise criteria (myocardial edema and late gadolinium enhancement).
     • Exclusion of alternate causes (viral panel negative, ischemic causes ruled out).
4. Cold Chain and Storage Requirements:
   • mRNA Vaccines (BNT162b2):
     • Ultracold storage: $-90^\circ\text{C}$ to $-60^\circ\text{C}$ until expiration date.
     • Standard refrigeration ($+2^\circ\text{C}$ to $+8^\circ\text{C}$): Valid for up to 10 weeks (70 days) once thawed prior to dilution.
     • Post-dilution room temperature/refrigeration: Must be used within 6 hours; must not be refrozen.
   • Inactivated (Covaxin) & Protein Subunit (Corbevax) Vaccines:
     • Standard cold chain: $+2^\circ\text{C}$ to $+8^\circ\text{C}$.
     • Strictly protected from freezing; physical "Shake Test" mandatory if freezing is suspected.

1. Comparison of UIP vs. IAP ACVIP DPT Schedule:
   • Universal Immunization Programme (UIP):
     • Primary Series: 3 doses at 6, 10, and 14 weeks (as Pentavalent: DTwP-HepB-Hib).
     • First Booster: 16 to 24 months (DTwP).
     • Second Booster: 5 to 6 years (DTwP).
     • Adolescence: Td at 10 years and 16 years.
   • IAP ACVIP Schedule:
     • Primary Series: 3 doses at 6, 10, and 14 weeks (DTwP or DTaP combination).
     • First Booster: 15 to 18 months (DTwP / DTaP).
     • Second Booster: 4 to 6 years (DTwP / DTaP; wP preferred for primary and boosters by IAP, but aP permitted under specific clinical contexts).
     • Pre-adolescent / Adolescent Booster: Tdap at 10 years (and subsequent Td/Tdap every 10 years).
2. Absolute Contraindications vs. Precautions for Whole-Cell Pertussis (wP):
   • Absolute Contraindications (to any further pertussis-containing vaccine):
     • Anaphylaxis or immediate severe allergic reaction to a prior dose or vaccine component.
     • Encephalopathy not attributable to another identifiable cause occurring within 7 days of vaccine administration (defined as severe acute neurological illness with prolonged seizures, severe coma, or altered sensorium).
   • Precautions (where benefit-risk must be weighed, or switch to aP / DT is indicated):
     • High fever $\ge 40.5^\circ\text{C}$ ($\ge 105^\circ\text{F}$) within 48 hours not due to another cause.
     • Collapse or shock-like state (hypotonic-hyporesponsive episode [HHE]) within 48 hours.
     • Persistent, inconsolable crying lasting $\ge 3\text{ hours}$ occurring within 48 hours.
     • Convulsions (with or without fever) occurring within 72 hours.
     • Progressive/unstable neurological disorders (e.g., uncontrolled infantile spasms, progressive encephalopathy) until the condition has stabilized.
3. Catch-Up Plan for this 14-Month-Old Child:
   • Current status: Child had 2 doses of Pentavalent + bOPV; needs 1 dose to complete primary series, plus booster. The prior reaction (fever 39.8°C and local swelling) is a known side effect and a precaution, not an absolute contraindication. Switching to DTaP is recommended to reduce reactogenicity and avoid vaccination drop-out.
   • Visit 1 (Current - 14 Months):
     • Hexavalent (DTaP-IPV-HepB-Hib) IM OR Pentavalent (DTaP-HepB-Hib) + IPV (dose 3, completes primary series).
     • MMR-1 (SC).
   • Visit 2 (6 Months after Visit 1, at 20 Months):
     • First Booster: DTaP + IPV + Hib booster.
   • Subsequent Boosters:
     • DTaP / DTwP second booster at 4 to 6 years.
     • Tdap at 10 years.
4. Differences Between wP and aP Vaccines:
   • Composition:
     • wP: Suspensions of killed, whole Bordetella pertussis bacteria containing thousands of antigens and endotoxin (lipooligosaccharide).
     • aP: Purified, detoxified specific bacterial components: Pertussis toxoid (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3 (FIM 2/3).
   • Immunological Profile:
     • wP: Induces Th1 and Th17 cell-mediated immune responses and mucosal immunity; inhibits nasal colonization and transmission.
     • aP: Induces predominantly a Th2 response; provides excellent systemic protection against severe disease but poorer prevention of mucosal colonization and faster waning of immunity (median protection 3–5 years vs. 8–10 years for wP).
   • Reactogenicity: wP produces substantially higher rates of fever, erythema, swelling, febrile seizures, and HHE compared to aP.

1. Post-Exposure Prophylaxis (PEP) Protocol for Hepatitis A:
   • Time Window: PEP must be administered as early as possible, strictly within 14 days (2 weeks) of the last exposure to the index case.
   • Age-Stratified Recommendations:
     • Infants <12 months of age: Standard Normal Human Immunoglobulin (HNIG) is indicated.
     • Healthy individuals aged 12 months to 40 years: Single dose of Hepatitis A vaccine is preferred over immunoglobulin due to equivalent efficacy, longer duration of protection, and ease of administration.
     • Persons >40 years, immunocompromised individuals, or patients with chronic liver disease: Immunoglobulin (HNIG) is preferred; Hepatitis A vaccine may be given simultaneously at a separate anatomical site.
2. Prophylactic Plan for the Two Siblings:
   • 3-Year-Old Sister (Weight 14 kg):
     • Give Hepatitis A vaccine immediately (within 14 days of contact).
     • Option A (Live attenuated H2 strain): $0.5\text{ mL}$ subcutaneously as a single dose (no booster required).
     • Option B (Inactivated vaccine): Age-appropriate pediatric dose ($0.5\text{ mL}$ containing $\ge 720\text{ ELISA units}$ or $80\text{ units}$ depending on brand) IM in the anterolateral thigh or deltoid. Schedule a second (booster) dose at 6 months to ensure long-term immunity.
   • 4-Month-Old Infant Brother:
     • Hepatitis A vaccine is not licensed or immunogenic under 12 months due to interference from maternal antibodies.
     • Administer Normal Human Immunoglobulin (HNIG):
       $$ > \begin{aligned} > \text{Dose of HNIG} &= 0.1\text{ mL/kg (for exposure within 2 weeks)} \\ > &= 0.1 \times \text{Weight in kg} \quad (\text{deep intramuscular injection}) > \end{aligned} > $$
     • Provide regular soap-and-water hand hygiene instruction to parents; advise routine Hepatitis A vaccination after the infant turns 12 months old.
3. Comparison of Hepatitis A Vaccines in India:
   • Inactivated (Killed) Hepatitis A Vaccine (e.g., Havrix, Avaxim, Bio-Vac A):
     • Strain: HM175 or CR326 strain grown in human diploid cells (MRC-5), formalin-inactivated, adjuvanted with aluminum hydroxide.
     • Schedule: 2-dose series (Dose 1 at $\ge 12\text{ months}$; Dose 2 given 6 to 12 months after the first dose).
     • Route & Dose: $0.5\text{ mL}$ Intramuscularly (IM).
     • Efficacy/Durability: Seroconversion >99%; antibody persistence >25 to 30 years.
   • Live Attenuated Hepatitis A Vaccine (e.g., Biovac-A):
     • Strain: H2 strain grown in human diploid cells.
     • Schedule: Single dose at $\ge 12\text{ months}$; no booster dose is routinely recommended by the manufacturer/IAP.
     • Route & Dose: $0.5\text{ mL}$ Subcutaneously (SC).
     • Efficacy/Durability: High seroconversion (>95%); long-term immunologic memory documented for over 15 years.
4. High-Risk Pediatric Populations Requiring Routine Hepatitis A Vaccination:
   • Children with Chronic Liver Disease (e.g., Wilson disease, biliary atresia post-

1. Immediate Neonatal Post-Exposure Prophylaxis:
   • Hepatitis B Immune Globulin (HBIG):
     • Dose: $0.5\text{ mL}$ ($100\text{--}200\text{ IU}$) intramuscularly (IM) within 12 hours of life (preferably within 6 hours).
     • Site: Anterolateral thigh (vastus lateralis).
   • Monovalent Hepatitis B Vaccine:
     • Dose: $0.5\text{ mL}$ ($10\ \mu\text{g}$) IM administered simultaneously within 12 hours of life.
     • Site: Contralateral anterolateral thigh (opposite limb from HBIG) using a separate needle and syringe.
   • Subsequent Series:
     • Completion of the routine immunization series at 6, 10, and 14 weeks (using pentavalent/hexavalent vaccine) or monovalent doses at 0, 1, and 6 months; the birth dose is considered dose 0 if a combined vaccine is used later.
2. Post-Vaccination Serologic Testing in the Infant:
   • Timing: Conduct testing at 9 to 12 months of age (or 1 to 2 months following the final dose of the primary vaccine series; never before 9 months to avoid detecting passively acquired maternal anti-HBs or passively infused HBIG).
   • Parameters Measured:
     • Serum anti-HBs (quantitative antibody to surface antigen).
     • Serum HBsAg (to assess for breakthrough chronic infection).
   • Interpretation:
     • Anti-HBs $\ge 10\text{ mIU/mL}$ and HBsAg-negative: Protected/immune.
     • Anti-HBs $< 10\text{ mIU/mL}$ and HBsAg-negative: Non-responder; administer a second 3-dose series and re-test.
     • HBsAg-positive: Perinatal infection established; refer for pediatric hepatology follow-up.
3. High-Risk Populations Warranting Post-Vaccination Serology:
   • Children receiving chronic hemodialysis or with end-stage renal disease (ESRD).
   • Human Immunodeficiency Virus (HIV) infected children and adolescents.
   • Immunocompromised individuals (e.g., hematopoietic stem cell transplant recipients, patients on active cytotoxic chemotherapy, solid organ transplant recipients).
   • Healthcare personnel and individuals with frequent occupational risk of blood/body fluid exposure.
   • Sex partners or household contacts of chronic HBsAg-positive persons.
4. Definition and Management of Non-Responders:
   • Definition: Failure to achieve an anti-HBs titer $\ge 10\text{ mIU/mL}$ measured 1 to 2 months after receiving a complete, documented 3-dose primary immunization series.
   • Revaccination Strategy:
     • Administer a second complete 3-dose series (0, 1, 6 months) with standard or high dose ($20\ \mu\text{g}$ or $40\ \mu\text{g}$ formulation, especially in dialysis/immunosuppression), re-testing anti-HBs 1 to 2 months after the final dose.
     • Alternatively: Give one challenge dose; if anti-HBs $\ge 10\text{ mIU/mL}$ at 1 month, patient had anamnestic response; if $< 10\text{ mIU/mL}$, complete remaining 2 doses of the second series.
   • Persistent Non-Responders (anti-HBs $< 10\text{ mIU/mL}$ after 6 documented doses):
     • Screen for occult chronic infection (test HBsAg, total anti-HBc).
     • If negative, counsel that individual is susceptible.
     • Post-Exposure Management: Following parenteral or mucosal exposure to HBsAg-positive source, administer two doses of HBIG ($0.06\text{ mL/kg}$ or adult standard $5\text{ mL}$ IM), the first dose immediately within 24 hours and the second dose 1 month later.

1. Principles of Simultaneous Vaccine Co-Administration:
   • Safety and Immunogenicity: All routine pediatric inactivated and live attenuated vaccines can be administered simultaneously during the same clinical encounter without diminishing immune response or increasing reactogenicity.
   • Administration Technique:
     • Each injectable vaccine must be drawn into a separate sterile syringe with an individual needle.
     • Vaccines must never be mixed together in the same syringe unless specifically licensed and manufactured as a combined product (e.g., DTwP-HepB-Hib).
     • Injections must be administered at distinct anatomical sites separated by at least 2.5 cm (1 inch) to allow accurate localized adverse event assessment.
     • In toddlers, both anterolateral thighs and both deltoid muscles can be utilized.
2. Hib Conjugate Vaccine Carrier Proteins:
   • PRP-T (Polyribosylribitol phosphate conjugated to Tetanus Toxoid):
     • Carrier: Purified tetanus toxoid protein ($20\ \mu\text{g}$ per dose).
     • Immunogenicity: T-cell dependent response; requires 3 primary infant doses to achieve early protective titers; robust booster response.
   • PRP-OMP (Conjugated to Outer Membrane Protein Complex of Neisseria meningitidis serogroup B):
     • Carrier: Meningococcal outer membrane protein complex ($250\ \mu\text{g}$).
     • Immunogenicity: Rapid anti-PRP antibody rise after a single primary infant dose, offering earlier protection; 2 primary doses suffice.
   • HbOC (Conjugated to CRM197 mutant Diphtheria toxin):
     • Carrier: Non-toxic mutant diphtheria protein CRM197 ($25\ \mu\text{g}$).
     • Uses oligosaccharide chains instead of long polysaccharides; requires 3 infant primary doses.
3. Catch-Up Hib Vaccination Schedule (12 to 59 Months):
   • Child Aged 12 to 14 Months (Partially Immunized):
     • If received 0 doses previously: Administer 2 doses, spaced 8 weeks (minimum 4 weeks) apart.
     • If received 1 dose before 12 months: Administer 2 additional doses, 8 weeks apart.
     • If received 2 doses before 12 months: Administer 1 final booster dose at least 8 weeks after the last dose.
   • Child Aged 15 to 59 Months:
     • Requires only one single dose of any licensed Hib conjugate vaccine, irrespective of prior vaccination history.
   • Children $\ge 60$ Months:
     • Routine Hib vaccination is not recommended in healthy immunocompetent children $\ge 5$ years of age.
     • Mandatory 1 dose for high-risk conditions (anatomical or functional asplenia, sickle cell disease, HIV, elective splenectomy, complement deficiency, post-chemotherapy).
4. Storage and Reconstitution Stability:
   • Storage: Maintain at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$. Must never be frozen (freezing damages the liquid adjuvant or protein carrier).
   • Diluent: Specific manufacturer-supplied 0.4% or 0.9% sodium chloride diluent (or liquid DTwP/DTaP-HepB in combination formulations).
   • Post-Reconstitution Time Limit: Must be administered immediately or strictly within 4 hours if stored at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$; any unused reconstituted vaccine must be discarded at the end of the immunization session.

1. Gender-Neutral Vaccination (GNV):
   • Definition: Universal immunization policy recommending and providing HPV vaccination to all eligible adolescents irrespective of biological sex (both females and males).
   • Advantages:
     • Direct Protection in Males: Prevents HPV-associated anogenital cancers (anal, penile), oropharyngeal squamous cell carcinoma, and anogenital warts (condylomata acuminata) in boys.
     • Herd Immunity: Dramatically interrupts community transmission of high-risk HPV types, providing indirect protection to unvaccinated females.
     • Resilience Against Sub-Optimal Coverage: Ensures disease reduction even when female vaccination coverage rates are moderate or low.
     • Protection of High-Risk Subpopulations: Protects men who have sex with men (MSM) who do not benefit from female-only herd immunity programs.
2. Formulations Licensed in India:
   • Bivalent Vaccine (Cervarix / Cecolin):
     • Antigens: Virus-Like Particles (VLPs) of HPV types 16 and 18.
     • Prevention: Cervical intraepithelial neoplasia (CIN 2/3), cervical adenocarcinoma, and invasive squamous cervical cancer.
   • Quadrivalent Vaccine (Gardasil / Cervavac):
     • Antigens: VLPs of HPV types 6, 11, 16, and 18.
     • Prevention: Cervical cancer, vulvar/vaginal pre-cancers, anal cancer, and genital warts (types 6, 11).
   • Nonavalent Vaccine (Gardasil-9):
     • Antigens: VLPs of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
     • Prevention: Expanded coverage preventing approximately 90% of cervical cancers, high-grade cervical dysplasia, and extra-cervical HPV malignancies.
3. Age-Stratified Dosing Schedules:
   • Age 9 to 14 Years (Immunocompetent):
     • 2-Dose Schedule: Administered at 0 and 6 months (acceptable minimum interval between doses is 5 to 6 months; if dose 2 is given $<5$ months after dose 1, a third dose is mandatory).
     • Note: WHO 2022 guidelines also acknowledge an alternative single-dose schedule for public health programs in girls aged 9–14 years; however, IAP/ACVIP continues to recommend the 2-dose regimen.
   • Age $\ge 15$ Years up to 26 / 45 Years:
     • 3-Dose Schedule: Administered at 0, 1 to 2, and 6 months (0, 1, 6 months for bivalent; 0, 2, 6 months for quadrivalent and nonavalent).
     • Minimum intervals: 4 weeks between dose 1 and 2; 12 weeks between dose 2 and 3; minimum 5 months between dose 1 and 3.
   • Immunocompromised Individuals (Any Age, including HIV-Infected):
     • Mandatory 3-Dose Schedule (0, 1–2, 6 months) regardless of age at initiation.
4. Upper Age Limits and Special Situations:
   • Catch-Up Upper Age Limit: Recommended routinely up to 26 years; licensed and approved for shared clinical decision-making up to 45 years of age.
   • Pregnancy: Not recommended during pregnancy. If a female becomes pregnant after initiating the series, remaining doses must be postponed until delivery. Pregnancy testing prior to vaccination is not required; accidental administration is not an indication for pregnancy termination.
   • Lactation: HPV vaccines are non-infectious subunit VLP vaccines and can be safely administered to lactating/breastfeeding mothers.

1. Immunization Modifications in HIV-Exposed / Infected Infants:
   • BCG:
     • WHO/IAP: Administer at birth if the infant is asymptomatic and maternal viral load is well-controlled. Withhold BCG if the infant has clinical signs of HIV or severe immunosuppression.
   • Polio Vaccine:
     • OPV is contraindicated in HIV-infected infants and household contacts of HIV-infected individuals due to the risk of Vaccine-Associated Paralytic Poliomyelitis (VAPP).
     • Administer Inactivated Polio Vaccine (IPV) exclusively.
   • Rotavirus Vaccine:
     • Can be safely administered to HIV-exposed or asymptomatic/mildly symptomatic HIV-infected infants per standard schedule (benefit outweighs theoretical risk).
   • Measles / MMR:
     • Administer at 9 months (Measles/MR) and 12–15 months (MMR) unless there is evidence of severe immunosuppression (see question 4).
2. Clinical Spectrum of Post-BCG Lymphatic Complications:
   • Non-Suppurative BCG Lymphadenitis:
     • Benign, ipsilateral regional (axillary or supraclavicular) lymph node enlargement ($>1\text{ cm}$) occurring 2 to 6 months post-vaccination; firm, non-tender, mobile, without overlying erythema, spontaneously resolving over months without suppuration.
   • Suppurative BCG Lymphadenitis:
     • Development of fluctuation, erythema, purulent softening, caseation, and spontaneous purulent fistula/sinus formation adhering to overlying skin.
   • Disseminated BCG Infection (BCG-osis):
     • Systemic mycobacterial dissemination to distant sites (bone, liver, spleen, lungs, distant lymph nodes) occurring almost exclusively in primary immunodeficiencies (e.g., SCID, MSMD) or advanced HIV infection with CD4 exhaustion; life-threatening.
3. Management Protocol for the Infant's Axillary Lymph Node:
   • Current Presentation (Non-Suppurative BCG Lymphadenitis):
     • Expectant Observation: Reassurance and close clinical monitoring every 4 weeks. Most resolve spontaneously over 4 to 6 months.
     • Medical Therapy: Standard oral anti-tubercular therapy (e.g., Isoniazid, Rifampicin) is ineffective and not indicated (M. bovis BCG is inherently resistant to Pyrazinamide).
   • If Fluctuant / Suppurative:
     • Needle Aspiration: Perform needle aspiration using a wide-bore needle (18–20G) entering via non-dependent normal skin to decompress, relieve tension, and prevent sinus tract formation. May repeat if fluid re-accumulates.
   • Absolute Contraindication:
     • Incision and Drainage (I&D) is strictly contraindicated because it invariably results in chronic, non-healing sinus tract formation, secondary bacterial infection, and prolonged scarring.
4. Immunologic Criteria for Live Viral Vaccines (MMR/Varicella) in HIV:
   • Administer only if the child is not severely immunocompromised, defined by age-specific CD4 T-cell parameters:
     • Age $<12\text{ months}$: CD4 percentage $\ge 25\%$ (or absolute CD4 count $\ge 750/\mu\text{L}$).
     • Age 1 to 5 years: CD4 percentage $\ge 15\%$ (or absolute CD4 count $\ge 500/\mu\text{L}$).
     • Age $\ge 6$ years: CD4 percentage $\ge 15\%$ (or absolute CD4 count $\ge 200/\mu\text{L}$).
   • If CD4 criteria are met, MMR should be administered at 9 and 12–15 months.

1. Immunization Protocol in Bleeding Disorders:
   • Route Selection: Prefer subcutaneous (SC) or intradermal route if officially approved and licensed for that specific vaccine. However, for adjuvanted vaccines (DTwP, DTaP, HepB, Hib, PCV, HPV), intramuscular (IM) administration is required to prevent subcutaneous sterile granulomas/cysts.
   • Clotting Factor Optimization: Schedule elective IM vaccinations immediately following a scheduled Factor VIII prophylactic infusion, when factor levels are at peak ($>30\%$).
   • Technique:
     • Use a fine-gauge needle: 23-gauge or smaller (e.g., 25-gauge).
     • Apply firm, continuous digital pressure to the injection site without rubbing or massaging for a minimum of 5 full minutes.
     • Instruct parents to monitor the limb for expanding hematoma, swelling, or neurovascular compromise over 24 to 48 hours.
2. Cold Chain Storage Classification:
   • Can Be Safely Stored in Freezer Compartment ($-15^\circ\text{C}\text{ to }-25^\circ\text{C}$):
     • Oral Polio Vaccine (OPV).
     • Lyophilized Measles / MR / MMR vaccines (though routinely kept at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$, freezing does not damage the lyophilized cake; diluent must NEVER be frozen).
   • Must NEVER Be Frozen (Damaged by Freezing; Store Strictly at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$):
     • Pentavalent (DTwP-HepB-Hib).
     • Hepatitis B monovalent vaccine.
     • Inactivated Polio Vaccine (IPV).
     • Liquid Rotavirus vaccine.
     • Pathophysiology: Freezing breaks the aluminum adjuvant emulsion, creating jagged mineral agglomerates that irreversibly destroy immunogenicity and cause severe injection-site reactogenicity.
3. The Shake Test Protocol:
   • Purpose: To determine if an aluminum-adjuvanted vaccine has suffered irreversible freeze damage.
   • Procedure:
     • Take a suspect vial and a known "control" vial of the same manufacturer and batch that was deliberately frozen solid at $-20^\circ\text{C}$ for 24 hours and then thawed.
     • Shake both vials vigorously for 10 to 15 seconds simultaneously.
     • Place both vials side by side on a flat surface against a light source to observe sedimentation dynamics.
   • Interpretation:
     • Pass (Safe to use): Suspect vial sediment settles much slower than the frozen control vial; fluid remains cloudy/turbid longer.
     • Fail (Freeze-damaged; discard): Suspect vial sediment settles rapidly (within 15–30 minutes), leaving a clear supernatant liquid and a dense clumped pellet at the bottom, settling at the same speed or faster than the frozen control.
4. Post-Reconstitution Time Limits (Cold Chain $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$):
   • BCG: Must be used within 4 hours; discard any remaining reconstituted vaccine after 4 hours.
   • Measles / MR / MMR: Must be used within 4 hours; discard after 4 hours (lacks preservative; risk of toxic shock syndrome due to Staphylococcus aureus contamination and rapid drop in viral titer at ambient temperatures).
   • Japanese Encephalitis (Live SA 14-14-2): Must be used strictly within 2 hours of reconstitution; discard any remaining amount after 2 hours.
5. Pre-Splenectomy Immunization Protocol (Age 4 Years):
   • Timing: Complete all vaccines at least 14 days (preferably $\ge 2$ weeks) prior to elective splenectomy to achieve adequate antibody titers.
   • Target Organisms & Vaccines:
     • Pneumococcus:
       • Administer Pneumococcal Conjugate Vaccine (PCV13 or PCV15) immediately.
       • Follow with 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) administered at least 8 weeks after PCV.
       • Revaccinate with PPSV23 once after 5 years.
     • Meningococcus:
       • Administer Quadrivalent Meningococcal Conjugate Vaccine (MenACWY - Menactra or Menveo): 2-dose primary series spaced 8 weeks apart.
       • Booster dose every 5 years throughout life asplenic status.
     • Haemophilus influenzae type b (Hib):
       • Administer 1 dose of Hib conjugate vaccine if not fully vaccinated in infancy.
     • Influenza: Annual inactivated influenza vaccine (injectable formulation only).

1. Definitions and Delivery Methods:
   • IPV: Inactivated Poliovirus Vaccine (Salk / enhanced-potency IPV [eIPV]); administered intramuscularly (IM) or deep subcutaneously at a standard full dose of $0.5\text{ mL}$.
   • fIPV: Fractional-dose Inactivated Poliovirus Vaccine; administered intradermally (ID) at one-fifth of the full dose ($0.1\text{ mL}$), typically over the right deltoid using an auto-disable (AD) syringe to achieve sparing of vaccine stock while stimulating robust dermal dendritic antigen presentation.
2. IAP IPV Schedule:
   • Primary Series: 3 doses given at 6, 10, and 14 weeks of age.
   • First Booster: 16 to 18 months of age.
   • Recent Guideline Update: A second booster dose of IPV is recommended at 4 to 6 years of age (replacing the standalone OPV booster to complete an all-IPV schedule and mitigate vaccine-associated paralytic poliomyelitis [VAPP] / circulating vaccine-derived poliovirus [cVDPV] emergence).
3. Universal Immunization Program (UIP) fIPV Schedule:
   • Dose 1: 6 weeks ($0.1\text{ mL}$, intradermal, right deltoid).
   • Dose 2: 14 weeks ($0.1\text{ mL}$, intradermal, right deltoid).
   • Dose 3 (Third fractional dose introduced nationwide): 9 completed months along with MR-1 ($0.1\text{ mL}$, intradermal, left upper arm).
4. Vaccine Vial Monitor (VVM) Interpretation:
   • Principle: A heat-sensitive chemical indicator label containing an inner square inside an outer circle that darkens progressively with cumulative heat exposure.
   • Stage 1: Inner square is lighter than outer circle $\rightarrow$ Vaccine can be used.
   • Stage 2: Inner square is still lighter than outer circle, but has started darkening $\rightarrow$ Vaccine can be used (use first).
   • Stage 3 (Discard point): Inner square matches the color of the outer circle $\rightarrow$ DO NOT USE; discard vial immediately.
   • Stage 4: Inner square is darker than the outer circle $\rightarrow$ DO NOT USE; discard vial immediately.

1. Target Populations:
   • Children living in designated endemic districts (routine programmatic coverage).
   • Laboratory personnel working with viable Japanese encephalitis virus.
   • Travelers planning prolonged stays ($\ge 4\text{ weeks}$) in endemic areas during transmission seasons, or travelers with extensive outdoor/rural exposure in endemic zones.
2. Comparative Schedule for Live Attenuated SA 14-14-2 Vaccine:
   • Universal Immunization Program (UIP):
     • Dose 1: 9 completed months to 12 months (administered along with MR-1).
     • Dose 2: 16 to 24 months (administered along with MR-2 / DPT booster).
   • Indian Academy of Pediatrics (IAP):
     • Minimum age: 8 months (or 9 months per revised recommendations).
     • Primary single dose at 9 months; a second dose is recommended at 12–24 months (or a single dose for inactivated vero-cell derived JE vaccine at 15–18 months with booster after 1 year depending on brand).
3. Vaccine Types Licensed in India:
   • Live Attenuated Vaccine (SA 14-14-2): Primary cell-culture derived; Dose: $0.5\text{ mL}$, Route: Subcutaneous (SC).
   • Inactivated Vero Cell-derived Vaccine (e.g., JENVAC / IC-51 / KFD strain):
     • JENVAC (strain 821564XY): Dose $0.5\text{ mL}$ IM; 2 doses 28 days apart (or 1 dose with booster at 1 year).
     • JEEV (inactivated purified SA 14-14-2 on Vero cells): Dose $0.25\text{ mL}$ ($2.5\ \mu\text{g}$) for children $\le 3\text{ years}$, $0.5\text{ mL}$ ($5\ \mu\text{g}$) for $>3\text{ years}$; 2 doses IM on days 0 and 28.
   • Recombinant Live Chimeric Vaccine (JE-CV / IMOJEV): Single dose $0.5\text{ mL}$ SC.
4. Contraindications to Live Attenuated JE Vaccine (SA 14-14-2):
   • Severe congenital or acquired immunodeficiency disorders (e.g., advanced HIV infection, severe combined immunodeficiency, symptomatic malignant neoplasms).
   • Concurrent immunosuppressive therapy (e.g., systemic high-dose corticosteroids, antimetabolites, alkylating agents).
   • Severe hypersensitivity/anaphylaxis to any vaccine component or previous dose.
   • Pregnancy.

1. Definition and Thermodynamic Principle of Lyophilization:
   • Definition: Lyophilization (freeze-drying) is a low-temperature dehydration process in which a biological product is frozen and the solvent (water) is removed directly from the solid state to the vapor state.
   • Principle: Operates on the principle of sublimation under reduced vacuum/pressure, bypassing the liquid phase. This minimizes thermal degradation of delicate protein antigens and viral capsids, yielding a stable dry powder with prolonged shelf-life.
2. Lyophilized Pediatric Vaccines (any four):
   • Bacille Calmette-Guérin (BCG) vaccine.
   • Measles / Measles-Rubella (MR) / Measles-Mumps-Rubella (MMR) vaccine.
   • Live attenuated Japanese Encephalitis vaccine (SA 14-14-2).
   • Varicella vaccine.
   • Lyophilized Rabies vaccine (cell-culture derived).
   • Yellow fever vaccine.
3. Diluent Storage and Handling Guidelines:
   • Diluents are product- and manufacturer-specific; never interchange diluents between different vaccines or manufacturers.
   • Diluents do not require sub-zero storage during prolonged stockpiling, but must be chilled to $+2^\circ\text{C}$ to $+8^\circ\text{C}$ for at least 24 hours prior to reconstitution to avoid thermal shock to antigens upon mixing.
   • Diluents must never be frozen.
4. Post-Reconstitution Discard Timeline (Open Vial Policy Rules):
   • Lyophilized reconstituted vaccines are strictly exempt from the multi-dose Open Vial Policy.
   • BCG, MR/MMR, and JE vials must be discarded within 4 hours of reconstitution (or at the end of the immunization session, whichever is earlier).
   • Reasons: Lack of preservatives in reconstituted live vaccines exposes them to rapid bacterial contamination (e.g., Staphylococcus aureus leading to Toxic Shock Syndrome) and progressive rapid loss of biological potency at ambient room temperature.

1. Mission Indradhanush Definition and Target:
   • Definition: A targeted national catch-up immunization drive designed to achieve $>90\%$ full immunization coverage (FIC) across India.
   • Target Population: All children aged up to 2 years and pregnant women who have been missed, partially vaccinated, or dropped out from routine UIP schedules, focusing on high-risk geographic areas (urban slums, nomadic settlements, brick kilns, underserved forested/tribal belts).
2. Launch Details:
   • Date of Launch: 25th December 2014 (Good Governance Day).
   • Authority: Ministry of Health and Family Welfare (MoHFW), Government of India.
3. Intensified Mission Indradhanush (IMI) & Focus of IMI 5.0:
   • IMI Evolution: Intensified door-to-door headcounts, inter-departmental convergence, reduced interval between rounds, and targeted microplanning in low-performing districts.
   • IMI 5.0 Special Focus:
     • First campaign conducted across all districts in all states/UTs involving children up to 5 years of age (expanded from $\le 2\text{ years}$).
     • Focused campaign for the elimination of Measles and Rubella (MR) by administering missed MR-1 and MR-2 doses.
     • Complete operational pilot and scale-up of the U-WIN digital platform for registration, tracking, and certification.
4. Digital Platforms Comparison:
   • eVIN (electronic Vaccine Intelligence Network): Digitizes vaccine supply chain logistics, providing real-time visibility into vaccine stock levels and cold-chain temperatures (using digital data loggers) across all cold-chain points nationally.
   • CoWIN (Covid Vaccine Intelligence Network): Scaled platform developed exclusively for nationwide planning, beneficiary registration, slot scheduling, and real-time verifiable QR-coded digital certification for COVID-19 vaccination.
   • U-WIN (Universal Immunization Network): Replicated from CoWIN for the Universal Immunization Program to maintain a permanent, computerized, name-based registry of pregnant women and infants from birth to 16 years, tracking individual dropouts, scheduling due vaccines, and issuing digital vaccination certificates.

1. Routine Vaccination Schedule:
   • Universal Immunization Program (UIP):
     • MR Vaccine (Measles-Rubella bivalent).
     • Dose 1: 9 completed months to 12 months ($0.5\text{ mL}$, subcutaneous, right upper arm).
     • Dose 2: 16 to 24 months ($0.5\text{ mL}$, subcutaneous, right upper arm).
   • Indian Academy of Pediatrics (IAP):
     • MMR Vaccine (Measles-Mumps-Rubella trivalent).
     • Dose 1: 9 months of age (MMR or MR).
     • Dose 2: 15 months of age (MMR).
     • Dose 3: 4 to 6 years of age (MMR).
2. Catch-up Schedule for a 15-Month-Old:
   • Administer the first dose of MMR immediately at the current encounter (15 months).
   • Administer the second dose of MMR at a minimum interval of 4 to 8 weeks (preferably 8 weeks) after the first dose.
   • A final booster dose should be administered at 4 to 6 years of age (ensuring at least 4 weeks interval from prior dose if given later).
3. Absolute Contraindications:
   • Severe anaphylaxis or life-threatening hypersensitivity reaction to a previous dose or to vaccine constituents (e.g., neomycin or gelatin; egg allergy is not a contraindication).
   • Severe congenital or acquired immunodeficiency state (e.g., severe combined immunodeficiency [SCID], hypogammaglobulinemia, leukemia, lymphoma, cellular immunodeficiencies, or symptomatic advanced HIV with severe immunosuppression [CD4 $<15\%$]).
   • High-dose systemic corticosteroid therapy ($\ge 2\text{ mg/kg/day}$ or $\ge 20\text{ mg/day}$ of prednisone equivalent for $\ge 14$ consecutive days; wait at least 1 month after cessation).
   • Pregnancy (in adolescent/adult females; avoid pregnancy for 4 weeks following vaccination).
4. Adverse Events Following Immunization (AEFI) with MMR:
   • Fever ($\ge 39.4^\circ\text{C}$): Occurs in 5%–15% of recipients; onset typically 7 to 12 days after immunization; lasts 1–2 days.
   • Transient Morbilliform Rash: Occurs in ~5% of recipients; onset 7 to 10 days post-vaccination.
   • Febrile Seizures: Incidence approximately 1 in 3,000 to 4,000 doses; peaks between 6 and 14 days post-vaccination (secondary to the measles-induced febrile peak; non-deleterious long-term prognosis).
   • Immune Thrombocytopenic Purpura (ITP): Incidence approximately 1 in 30,000 to 40,000 vaccinated children; manifests typically within 2 to 6 weeks following vaccination; usually transient and self-limiting.
   • Transient Arthralgia / Acute Arthritis: Most common in post-pubertal females (up to 25%); onset 1 to 3 weeks post-vaccination, persisting for 1 day to 3 weeks (rubella component).

graph TD
    A[Child Presents with Delayed / Missed Doses] --> B{Age Assessment}
    B -->|Age 9 to 12 Months| C[Give MR/MMR Dose 1]
    B -->|Age > 12 Months, Zero Doses| D[Give MMR Catch-Up Dose 1 Immediately]
    D --> E[Wait Minimum 4 to 8 Weeks]
    E --> F[Give MMR Catch-Up Dose 2]
    F --> G{Age at Dose 2}
    G -->|< 4 Years| H[Administer Dose 3 at 4-6 Years]
    G -->|≥ 4 Years| I[Primary Series Complete; No Further Doses Needed]

Key Clinical Distinction:

• Egg Allergy: The measles and mumps components are grown in chick embryo fibroblast tissue cultures, not in hen's eggs. Residual ovalbumin concentrations are negligible ($<1\text{ ng/dose}$); therefore, children with severe egg allergies (even anaphylaxis to egg) can safely receive the MMR vaccine without prior skin testing.
• Recent Blood Products: Live MMR vaccine replication can be inhibited by passively transferred maternal or therapeutic antibodies. The vaccine must be delayed for 3 to 11 months depending on the specific blood product (e.g., 3 months for packed RBCs, 8–11 months for high-dose intravenous immunoglobulin [IVIG]).

1. Open Vial Policy (OVP):
   • A policy permitting opened multi-dose vials of designated liquid vaccines to be stored and reused for subsequent immunization sessions for up to 28 days, provided all strict safety criteria are satisfied.
   • Mandatory criteria for reuse:
     • The vaccine expiry date has not passed.
     • The vial is stored continuously under recommended cold chain temperatures ($+2^\circ\text{C}$ to $+8^\circ\text{C}$).
     • Strict aseptic technique has been maintained (no submersion in water, septum not contaminated).
     • The Vaccine Vial Monitor (VVM), if present, has not reached or crossed the discard point.
     • The date and time of opening are legibly recorded on the vial label.
2. Vaccine Classification Under OVP:
   • Applicable (Liquid formulations with preservatives):
     • Oral Polio Vaccine (bOPV)
     • Pentavalent vaccine (DTP-HepB-Hib)
     • DTP (Diphtheria-Tetanus-Pertussis) and Td/TT (Tetanus-diphtheria)
     • Hepatitis B liquid vaccine
     • Injectable Inactivated Poliovirus Vaccine (fIPV / IPV)
     • Liquid Rotavirus vaccine (e.g., Rotavac)
     • Pneumococcal Conjugate Vaccine (liquid multi-dose presentation)
   • Exempt / Not Applicable (Reconstituted lyophilized vaccines - discard after 4 hours or at end of session):
     • BCG vaccine (must be discarded within 4 hours of reconstitution)
     • Measles-Rubella (MR) vaccine (discard within 4 hours)
     • Japanese Encephalitis (live attenuated SA-14-14-2 lyophilized; discard within 4 hours)
3. Vaccine Vial Monitor (VVM) Stages:
   • Stage 1 (Usable): Inner square is distinctly lighter than the outer circle.
   • Stage 2 (Usable): Inner square remains lighter than the outer circle, although slight darkening may have begun; use these vials first.
   • Stage 3 (Discard Point - Unusable): Inner square matches the colour of the outer circle exactly. Discard the vaccine.
   • Stage 4 (Beyond Discard Point - Unusable): Inner square is distinctly darker than the outer circle. Discard the vaccine.
4. Mathematical Derivation of Critical Vaccination Coverage ($V_c$):
   • Basic reproduction number ($R_0$): The average number of secondary infectious cases generated by a single index case introduced into a completely susceptible population.
   • Herd immunity threshold ($I_c$):
     $$ > I_c = 1 - \frac{1}{R_0} > $$
   • Critical vaccination coverage ($V_c$) taking vaccine effectiveness ($E$) into account:
     $$ > \begin{aligned} > V_c &= \frac{I_c}{E} = \frac{1 - \frac{1}{R_0}}{E} \\ > &= \frac{1 - \frac{1}{6}}{0.90} \\ > &= \frac{0.8333}{0.90} \\ > &= \mathbf{0.926} \quad (\mathbf{92.6\%}) > \end{aligned} > $$
   • Hence, a minimum immunization coverage of $92.6\%$ is required to interrupt community transmission.

1. Routine PCV Schedule Comparison:
   • Universal Immunization Programme (UIP):
     • $2 + 1$ schedule: Two primary doses at 6 weeks and 14 weeks, followed by a booster dose at 9 months of age ($0.5\text{ ml}$ IM anterolateral thigh).
   • Indian Academy of Pediatrics (IAP - ACVIP):
     • $3 + 1$ schedule: Three primary doses at 6, 10, and 14 weeks of age, followed by a booster dose at 12 to 15 months of age ($0.5\text{ ml}$ IM anterolateral thigh).
2. Catch-up Schedule for Sickle Cell Disease (Functional Asplenia) at 4 Years:
   • Step 1: Administer 1 dose of higher-valent Pneumococcal Conjugate Vaccine (PCV13 or PCV15), $0.5\text{ ml}$ intramuscularly into the deltoid muscle.
   • Step 2: Administer 1 dose of 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23), $0.5\text{ ml}$ IM or SC, at a minimum interval of 8 weeks after the PCV dose.
   • Step 3 (Revaccination): Administer a second dose of PPSV23 5 years after the first PPSV23 dose (maximum 2 PPSV23 doses in lifetime before age 65).
3. Newer Conjugate Formulations and Immunological Advantage:
   • Newer vaccines: PCV15 (contains serotypes 22F and 33F), PCV20 (adds serotypes 8, 10A, 11A, 12F, 15B, 22F, 33F), and PCV24.
   • Immunological advantage of conjugate vs polysaccharide:
     • T-cell dependent response: Conjugation of capsular polysaccharide to a carrier protein (e.g., $CRM_{197}$) recruits CD4+ T-helper cells, inducing robust high-avidity IgG production.
     • Immunological memory: Induces memory B cells, ensuring anamnestic responses upon re-exposure (unlike pure T-independent polysaccharide vaccines).
     • Mucosal immunity & carriage reduction: Reduces nasopharyngeal colonisation, conferring herd immunity.
     • Effective in children under 2 years of age (polysaccharide vaccines are poorly immunogenic under 24 months due to immature splenic marginal zone B cells).
4. Adverse Events and Minor Illness Guidance:
   • Common AEFI: Local erythema, swelling, induration, tenderness at injection site, irritability, transient decreased appetite, and low-grade fever.
   • Minor febrile illness: Mild upper respiratory tract infection with low-grade fever ($38.0^\circ\text{C}$) is not a contraindication. Vaccination should proceed without deferral. Vaccination should only be deferred in acute moderate-to-severe illness with high fever to avoid confounding disease manifestations with vaccine reactogenicity.

1. WHO / NCDC Exposure Category and Local Wound Management:
   • Category III Exposure: Single or multiple transdermal bites or scratches, licks on broken skin, contamination of mucous membranes with saliva, or any exposure to bats.
   • Immediate Wound Care:
     • Flush and wash all bite wounds, scratches, and adjacent skin immediately with running tap water and soap thoroughly for at least 15 minutes.
     • Apply a virucidal povidone-iodine ($5\%$) solution or other antiseptic after washing.
     • Avoid suturing wounds immediately. If suturing is essential for cosmetic or haemostatic reasons, infiltrate Rabies Immunoglobulin (RIG) first and delay suturing by at least 2 hours using loose, interrupted sutures.
2. Rabies Immunoglobulin (RIG) Calculation and Technique:
   • Dose Calculation:
     • Human RIG (hRIG): $20\text{ IU/kg}$
       $$ > \text{Dose} = 20\text{ IU/kg} \times 20\text{ kg} = \mathbf{400\text{ IU}} > $$
     • Equine RIG (eRIG): $40\text{ IU/kg}$
       $$ > \text{Dose} = 40\text{ IU/kg} \times 20\text{ kg} = \mathbf{800\text{ IU}} > $$
   • Administration Technique:
     • Infiltrate the maximum anatomically feasible volume of RIG thoroughly in and around the base and margins of all wounds.
     • Volume dilution: If the calculated volume is insufficient to infiltrate all multiple wound sites, dilute the RIG 2- to 3-fold in sterile normal saline ($0.9\%\text{ NaCl}$) to achieve adequate coverage.
     • If any calculated volume remains after wound infiltration, administer the remainder intramuscularly at an anatomical site distant from the vaccine site (e.g., anterolateral left thigh).
3. PEP Vaccine Regimens in Unimmunized Patients:
   • Intramuscular (IM) Essen Regimen (5 doses):
     • Administer 1 full vial ($0.5\text{ ml}$ or $1.0\text{ ml}$ depending on brand) IM in the anterolateral thigh (infants) or deltoid (older children) on Days 0, 3, 7, 14, and 28.
     • (Alternative: 4-dose Zagreb regimen: 2 doses on Day 0 at bilateral sites, 1 dose on Day 7, 1 dose on Day 21).
   • Intradermal (ID) Updated Thai Red Cross Regimen ($2\text{-site ID}$):
     • Administer $0.1\text{ ml}$ reconstituted cell-culture rabies vaccine intradermally at 2 separate sites (right and left deltoid) on Days 0, 3, and 7 (total of 6 injections).
     • Validated, cost-effective, and dose-sparing regimen endorsed by WHO and NCDC.
4. PEP Regimen in a Previously Immunized Individual (Re-exposure):
   • Wound Care: Immediate thorough washing with soap and water for 15 minutes.
   • RIG Requirement: Zero RIG. Rabies immunoglobulin is strictly not indicated and contraindicated as it interferes with the anamnestic memory response.
   • Vaccine Regimen (only 2 doses):
     • Intramuscular: 1 full vial on Day 0 and Day 3 (1 site each day).
     • Intradermal: $0.1\text{ ml}$ ID at 1 site on Day 0 and Day 3 (or $0.1\text{ ml}$ at 4 sites on Day 0 only per 2018 WHO update).

1. Age Limits for Rotavirus Vaccination:
   • First Dose:
     • Minimum age: 6 weeks.
     • Maximum age: 14 weeks and 6 days (as per conventional IAP guidelines; however, WHO recommends that if delayed, the first dose may still be administered along with DTP up to 2 years of age to avoid missing protection).
   • Final Dose:
     • Maximum age for any rotavirus vaccine dose: 8 months and 0 days (32 weeks).
     • Minimum interval between consecutive doses: 4 weeks.
2. Rotavirus Vaccine Formulations in India:
   • Rotavac (116E): Monovalent (G9P[11] human-bovine reassortant live attenuated, naturally occurring Indian neonatal strain). Requires 3 doses (at 6, 10, and 14 weeks); volume $0.5\text{ ml}$ (5 drops) orally.
   • RotaTeq (RV5): Pentavalent (human-bovine reassortant strains G1, G2, G3, G4, and P1A[8]). Requires 3 doses (at 6, 10, and 14 weeks); volume $2.0\text{ ml}$ orally.
   • Rotarix (RV1): Monovalent (attenuated human G1P[8] strain). Requires 2 doses (at 6 and 10 weeks); volume $1.5\text{ ml}$ orally.
   • ROTASIIL: Pentavalent (bovine-human reassortant strains G1, G2, G3, G4, G9 on bovine UK background). Requires 3 doses; available in lyophilized and liquid formulations.
3. Major Complication and Absolute Contraindications:
   • Intussusception:
     • Slight excess attributable risk (~1 to 5 cases per 100,000 vaccinated infants).
     • Peak temporal risk window: Within 7 to 21 days following the first dose (highest cluster in the first 7 days).
   • Absolute Contraindications:
     • History of documented prior intussusception.
     • Uncorrected congenital malformation of the gastrointestinal tract predisposing to intussusception (e.g., Meckel's diverticulum).
     • Severe Combined Immunodeficiency (SCID).
     • Severe anaphylactic reaction to a previous dose of rotavirus vaccine or its components.
4. Regurgitation and Breastfeeding Guidelines:
   • Regurgitation / Spitting:
     • If an infant spits out or vomits the vaccine dose, do not readminister or give a replacement dose. Proceed with the remaining doses in the schedule at the recommended intervals.
   • Breastfeeding interaction:
     • Although breast milk contains maternal anti-rotavirus secretory IgA antibodies, large clinical trials have demonstrated that breastfeeding does not significantly reduce overall seroconversion or clinical protective efficacy.
     • Breastfeeding should not be restricted or withheld before or after vaccine administration.

1. Antigenic Composition and Vaccine Types:
   • Antigenic Composition:
     • Standard formulations are Quadrivalent (containing two Influenza A subtypes: A/H1N1 and A/H3N2; and two Influenza B lineages: B/Victoria and B/Yamagata).
     • Note: WHO and US FDA have recommended transitioning to Trivalent formulations by removing the B/Yamagata lineage, as it has been extinct in global surveillance since March 2020.
   • Inactivated Influenza Vaccine (IIV):
     • Contains split-virion or subunit killed virus.
     • Administered via intramuscular (IM) injection ($0.5\text{ ml}$ into anterolateral thigh or deltoid).
     • Generates systemic serum neutralizing IgG antibodies directed against haemagglutinin (HA).
   • Live Attenuated Influenza Vaccine (LAIV):
     • Contains cold-adapted, temperature-sensitive reassortant live viruses that replicate only in the cooler nasopharynx ($25^\circ\text{C}$) but not in the lower respiratory tract ($37^\circ\text{C}$).
     • Administered via intranasal (IN) spray ($0.2\text{ ml}$ total: $0.1\text{ ml}$ per nostril).
     • Generates mucosal secretory IgA antibodies and cell-mediated immunity in addition to systemic IgG.
2. Dosing Schedule for This 3-Year-Old Child:
   • Primary Series Requirement: Children aged 6 months through 8 years receiving influenza immunization for the first time require 2 doses.
   • Dose & Route: $0.5\text{ ml}$ Intramuscular (deltoid or anterolateral thigh) per dose of Inactivated Quadrivalent Influenza Vaccine (IIV4).
   • Minimum Interval: 4 weeks between Dose 1 and Dose 2.
   • Subsequent Years: A single annual dose of $0.5\text{ ml}$ IM each autumn before the peak influenza season.
3. High-Risk Indications in Children:
   • Chronic pulmonary disorders (e.g., bronchial asthma, cystic fibrosis, bronchopulmonary dysplasia).
   • Hemodynamically significant congenital or acquired heart disease.
   • Chronic kidney disease and nephrotic syndrome.
   • Hemoglobinopathies (e.g., sickle cell disease, thalassemia major).
   • Immunosuppressive conditions (congenital immunodeficiencies, HIV infection, post-organ transplant, chemotherapy, or systemic corticosteroids).
   • Metabolic disorders (e.g., Type 1 Diabetes Mellitus).
   • Chronic neurological / neuromuscular disorders impairing respiratory clearance (e.g., cerebral palsy, spinal muscular atrophy).
   • Children receiving long-term aspirin therapy (risk of Reye syndrome post-wild influenza infection).
4. Contraindications Specific to LAIV (vs. IIV):
   • Children under 2 years of age (risk of wheezing/bronchospasm).
   • Children aged 2 to 4 years with active asthma or recurrent wheezing in the preceding 12 months.
   • Severe immunocompromise or immunodeficiency (primary cellular immunodeficiency, HIV with severe immunosuppression, post-transplantation).
   • Concomitant aspirin or salicylate-containing therapy in children/adolescents.
   • Cerebrospinal fluid (CSF) leak communicating with the nasopharynx or presence of cochlear implants.
   • Close household contact with severely immunosuppressed individuals requiring a protective environment (e.g., hematopoietic stem cell transplant recipients in isolation).

1. Rationale for Donor Deferral and Differential Diagnosis of Jaundice:
   • Deferral rationale: Jaundice may signify an acute or resolving viral hepatitis infection. Asymptomatic carriage, low-level viremia, or persistent viral replication during the "window period" pose a severe risk of transfusion-transmitted infections (TTIs) to vulnerable recipients.
   • Viral etiology: No, jaundice is not solely due to HBV. Other common etiologies include:
     • Viral: Hepatitis A (HAV), Hepatitis E (HEV), Hepatitis C (HCV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV).
     • Non-viral / Parasitic: Severe Plasmodium falciparum malaria, leptospirosis, sepsis.
     • Non-infectious: Gilbert syndrome, acute hemolysis (e.g., G6PD deficiency, autoimmune hemolytic anemia), drug-induced liver injury, biliary tract pathology.
2. Transfusion Transmission: HAV versus HCV:
   • Hepatitis A Virus (HAV):
     • Transmission risk: Extremely low.
     • Mechanism: HAV infection is self-limiting and lacks a chronic carrier state. Viremia is transient, lasting only 1–2 weeks preceding clinical jaundice, after which neutralizing antibodies clear the virus rapidly.
   • Hepatitis C Virus (HCV):
     • Transmission risk: High in unscreened units (historically the primary etiology of post-transfusion non-A, non-B hepatitis).
     • Mechanism: Up to 75–85% of HCV-infected individuals develop chronic persistent infection characterized by prolonged, low-level viremia and high propensity for progression to cirrhosis and hepatocellular carcinoma.
3. Protection Limits of Hepatitis B Vaccination Against Post-Transfusion Hepatitis:
   • Non-HBV Hepatotropic Pathogens: HBV vaccination induces anti-HBs antibodies, providing zero protection against other transfusion-transmissible hepatotropic agents (HCV, HEV, HAV, CMV, EBV, Parvovirus B19).
   • Occult Hepatitis B Infection (OBI) & Escape Mutants: Recipients with waning anti-HBs titers (<10 mIU/mL) or severe immunosuppression remain susceptible to high-inoculum HBV transfusion units. Furthermore, standard vaccine-induced antibodies directed against the "a" determinant may fail to neutralize HBV surface gene escape mutants (e.g., G145R).
4. Mandatory Donor Screening Tests in India (Drugs & Cosmetics Act):
   • Hepatitis B surface antigen (HBsAg) by ELISA or chemiluminescence immunoassay (CLIA).
   • Anti-Hepatitis C Virus antibody (anti-HCV) or HCV core antigen / NAT.
   • Anti-HIV-1 and anti-HIV-2 antibodies (or HIV-1/2 p24 antigen / NAT).
   • Serological test for Syphilis (Venereal Disease Research Laboratory [VDRL] or Rapid Plasma Reagin [RPR] or TPHA).
   • Malaria parasite screen (peripheral blood smear examination or rapid malarial antigen detection).

1. Travel-Specific Vaccines Indicated:
   • Yellow Fever Vaccine (17D strain): Mandatory for entry into Ghana and re-entry into India from endemic African regions.
   • Meningococcal Conjugate Vaccine (MenACWY): Required for travel through the African meningitis belt and for pilgrimage/entry regulations in Saudi Arabia.
   • Oral Polio Vaccine (OPV) / Inactivated Polio Vaccine (IPV) Booster: Mandatory single dose administered within 4 weeks to 12 months prior to travel between polio-affected or vulnerable countries under IHR temporary recommendations.
   • Typhoid Conjugate Vaccine (TCV) & Hepatitis A Vaccine: Strongly recommended endemic-risk travel vaccines.
2. Contraindications to Yellow Fever Vaccine:
   • Infants aged <6 months (high risk of Yellow Fever Vaccine-Associated Neurotropic Disease [YFV-AND]); relative contraindication/precaution between 6 and 8 months of age.
   • Severe hypersensitivity/anaphylaxis to egg proteins, gelatin, or any vaccine component.
   • Severe primary or acquired immunodeficiency (e.g., symptomatic HIV infection with CD4 <15% in children <5 years or CD4 <200/$\mu\text{L}$, severe combined immunodeficiency).
   • Thymus gland disorders (e.g., thymoma, myasthenia gravis, thymectomy).
   • Ongoing high-dose systemic immunosuppressive therapy (e.g., systemic corticosteroids $\ge$2 mg/kg/day or $\ge$20 mg/day of prednisone equivalent for $\ge$14 days, alkylating agents, antimetabolites, biologics).
3. Yellow Fever Vaccine Administration Details:
   • Dose & Route: 0.5 mL administered subcutaneously (or intramuscularly).
   • Diluent: Specific sterile physiological saline provided by the manufacturer (must be kept between +2°C and +8°C and used within 6 hours of reconstitution).
   • ICVP Validity: Becomes legally valid 10 days after primary vaccination and confers lifelong validity without the mandatory need for a 10-year booster dose (per WHO World Health Assembly 2014 amendment effective July 2016).
4. Quadrivalent Meningococcal Conjugate Vaccine (MenACWY) Protocol:
   • Dose & Route: 0.5 mL administered intramuscularly into the anterolateral thigh or deltoid muscle.
   • Product-Specific Schedule for 14-Month-Old:
     • MenACWY-TT (Nimenrix): Single dose of 0.5 mL IM if vaccinated at or after 12 months of age.
     • MenACWY-CRM (Menveo): If initiated between 7 and 23 months, 2 doses administered 3 months apart (with second dose administered at or after 12 months of age).
   • Booster Schedule: If the child remains at continued high risk or resides in an endemic zone, a booster dose is recommended every 5 years.

1. Recommendation and Clinical Rationale:
   • Recommendation: Yes, administer Typhoid Conjugate Vaccine (TCV) to both children immediately.
   • Rationale: While TCV will not abort an infection already acquired during the current incubation period, it provides robust pre-exposure immunity against ongoing, secondary household transmission and continuous endemic exposure. The children must simultaneously be monitored daily for fever and gastrointestinal symptoms to initiate immediate antibiotic therapy if illness develops.
2. Time to Protective Seroconversion and PEP Limitation:
   • Protective anti-Vi IgG seroconversion ($\ge$4-fold rise in antibody titer) requires 2 to 3 weeks (14–21 days) post-vaccination.
   • Enteric fever has a median incubation period of 7 to 14 days (range: 3–21 days depending on inoculum size).
   • Consequently, TCV cannot serve as effective abortive post-exposure prophylaxis for an infection contracted prior to or at the time of immunization.
3. Comparison: TCV vs. Unconjugated Vi Polysaccharide (Vi-PS):
   • Immunological Mechanism: TCV contains Vi polysaccharide conjugated to a carrier protein (tetanus toxoid), converting the antigen into a T-cell-dependent immunogen; Vi-PS is a pure T-cell-independent type-2 antigen.
   • Immune Memory: TCV induces B-cell memory and affinity maturation with anamnestic booster responses; Vi-PS does not induce immunologic memory and may induce hyporesponsiveness with repeated doses.
   • Age of Administration: TCV is immunogenic and approved from $\ge$6 months of age; Vi-PS is ineffective in infants and approved only at $\ge$2 years due to immaturity of the splenic marginal zone.
   • Efficacy and Durability: TCV provides sustained protective efficacy of $\approx$80–85% for at least 5–10 years; Vi-PS provides moderate efficacy (55–65%) that wanes rapidly after 2–3 years, requiring triennial revaccination.
4. IAP Recommendations for TCV:
   • Minimum Age: 6 months.
   • Dose & Route: 0.5 mL intramuscularly.
   • Primary Schedule: Single primary dose at 6 to 9 months of age (can be given anytime thereafter up to 45 years).
   • Booster: IAP Advisory Committee on Vaccines and Immunization Practices (ACVIP) recommends a booster dose between 2 and 3 years of age if the primary dose was received under 2 years of age.

1. MMR/MR and Varicella Administration and Skin Testing:
   • Recommendation: Both MR/MMR and Varicella vaccines should be administered at the routine scheduled age in full single doses without pre-vaccination allergy skin testing or desensitization protocols.
   • Safety Monitoring: Observe the infant for 15 to 30 minutes post-vaccination in a standard clinical setting where personnel and equipment (intramuscular epinephrine) are available to treat acute anaphylaxis.
2. Culture Medium and Ovalbumin Content Comparison:
   • MMR & Varicella: Measles and mumps viral strains are propagated in chick embryo fibroblast cultures (not whole embryonated eggs); rubella is grown in human diploid cell lines (WI-38/MRC-5); varicella is cultured in human diploid cells. They contain negligible or undetectable amounts of egg ovalbumin (picogram quantities), insufficient to provoke an IgE-mediated systemic reaction.
   • Inactivated Influenza Vaccine (IIV): Cultured in the allantoic fluid of embryonated chicken eggs. Modern formulations contain minimal ovalbumin ($\le$0.12 to 1 $\mu\text{g}$/0.5 mL dose), well below the threshold to trigger systemic reactions in most egg-allergic individuals.
   • Yellow Fever Vaccine: Cultured directly in living avian leukosis-free chick embryos. It contains substantial, measurable amounts of residual ovalbumin (microgram to milligram quantities) capable of eliciting life-threatening anaphylaxis in sensitized individuals.
3. Influenza Vaccine Protocol Based on Allergy Severity:
   • History of Urticaria Only:
     • Administer any age-appropriate licensed Inactivated Influenza Vaccine (IIV) in a routine outpatient setting.
     • Standard observation of 15 minutes. No special allergy testing or divided dosing is indicated.
   • History of Severe Egg Anaphylaxis (Hypotension, Wheezing, Angioedema, Recurrent Vomiting):
     • Administer any age-appropriate licensed IIV under direct medical supervision in a healthcare setting equipped with emergency resuscitation protocols (e.g., allergy clinic, pediatric emergency department, or hospital-based outpatient clinic).
     • Observe for 30 minutes post-injection.
4. Rabies and Yellow Fever Vaccines in Severe Egg Allergy:
   • Rabies Vaccine:
     • Purified Chick Embryo Cell Vaccine (PCECV) is cultured on chick embryo cells; avoid PCECV in patients with confirmed severe egg hypersensitivity.
     • Preferentially administer alternative cell-culture vaccines: Purified Vero Cell Rabies Vaccine (PVRV) or Human Diploid Cell Vaccine (HDCV).
     • If only PCECV is available following a Category III rabies exposure, administer it under strict anaphylaxis precautions with intramuscular epinephrine immediately available, as rabies disease has a 100% case fatality rate.
   • Yellow Fever Vaccine:
     • Truly contraindicated in severe egg allergy.
     • If travel to an active endemic transmission zone is unavoidable, refer to an allergist for vaccine prick testing (1:10 dilution) followed by intradermal testing (1:100 dilution). If positive, administer under a graded desensitization protocol in an intensive care setting.

1. Biological Classification of Specified Vaccines:
   • BCG: Live-attenuated bacterial vaccine (Mycobacterium bovis Danish 1331 strain).
   • bOPV: Live-attenuated viral vaccine (Sabin serotypes 1 and 3).
   • DTwP: Combination toxoids (Diphtheria toxoid, Tetanus toxoid) with inactivated whole-cell bacterial suspension (Bordetella pertussis).
   • Hib: Capsular polysaccharide (Polyribosylribitol phosphate - PRP) conjugated covalently to a carrier protein (e.g., Tetanus toxoid or CRM197).
   • Hepatitis B: Subunit recombinant surface antigen ($HBsAg$) synthesized via recombinant DNA technology in yeast (Saccharomyces cerevisiae) or mammalian cells.
   • Typhoid Vi: Unconjugated purified bacterial capsular polysaccharide.
   • Hepatitis A: Inactivated (killed) whole viral vaccine (formalin-inactivated HM175 or CR326 strain).
   • Acellular Pertussis (aP): Subunit vaccine composed of purified, inactivated bacterial antigens (pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], and fimbriae [FIM 2/3]).
2. T-Independent vs T-Dependent Antigen Processing:
   • Pure Polysaccharide (T-independent-2 antigen): Directly cross-links surface immunoglobulin receptors on mature B cells without MHC-II presentation. Fails to stimulate follicular T-helper ($T_{FH}$) cells; does not induce germinal center formation, affinity maturation, or immunologic memory. Children $<2$ years lack mature marginal zone B cells and complement receptor 2 (CD21), rendering pure polysaccharide vaccines clinically non-immunogenic in infancy.
   • Conjugate Vaccine (T-dependent antigen): The polysaccharide-protein conjugate is endocytosed by antigen-specific B cells; the protein carrier is degraded and presented via MHC-II to antigen-specific $CD4^+$ T-helper cells. This activates $CD40-CD40L$ co-stimulation and cytokine secretion, inducing germinal center formation, heavy-chain isotype class-switching from IgM to high-affinity IgG, and generation of long-lived memory B cells, conferring robust protection in infants $<2$ years.
3. Immune Response Characteristics:
   • Live Attenuated Vaccines: Replicate intracellularly, processed through endogenous pathways, presented via MHC Class I and Class II molecules; induce robust cytotoxic $CD8^+$ T-cell (CTL) responses, $CD4^+$ Th1 responses, circulating neutralizing IgG, and significant secretory IgA ($sIgA$) at mucosal surfaces.
   • Inactivated / Subunit Vaccines: Non-replicating, processed primarily through exogenous endosomal pathways and presented via MHC Class II; induce predominantly humoral neutralizing antibody (circulating IgG) and $CD4^+$ Th2 responses, with negligible cell-mediated cytotoxicity ($CD8^+$ CTL) and minimal to absent mucosal $sIgA$ induction unless administered mucosally.
4. Minimum Interval for Live Parenteral Vaccines:
   • 4 weeks (28 days). If two live parenteral vaccines (e.g., MMR and Varicella) are not administered on the same calendar day, an interval of $\ge 28$ days must be observed to prevent transient interferon-mediated immune interference from the first vaccine blunting replication of the second.

1. Equipment Identification and Liners:
   • Equipment: Standard Vaccine Carrier (Outreach Vaccine Carrier, WHO PQS compliant).
   • Packs Required: 4 conditioned coolant / ice packs ($0.3$ to $0.4\,\text{L}$ capacity each) lining all four interior vertical walls.
2. Ice Pack Conditioning and Physical Test:
   • Definition: The controlled thawing process of completely frozen ice packs (from $-15^\circ\text{C}$ to $-25^\circ\text{C}$) to bring their internal temperature to $0^\circ\text{C}$ before inserting them into the carrier, preventing freezing injury to freeze-sensitive vaccines.
   • Physical Verification Test:
     • Lay frozen packs flat on a clean surface at room temperature.
     • "Slosh / Sweat Test": Conditioning is complete when droplets of condensation appear on the external surface ("sweating") and a liquid water layer forms inside such that the ice core moves freely and sloshes distinctly when shaken against the ear.
3. Operational Parameters:
   • Cold Life: $12\text{ to }24\text{ hours}$ at $+43^\circ\text{C}$ ambient temperature (without being repeatedly opened; design specifications allow up to 30 hours for WHO-prequalified long-life carriers with lid fully closed).
   • Internal Storage Temperature: $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$.
4. Capacity and Operational Handling Rules:
   • Capacity: Accommodates 16 to 20 standard vaccine vials plus diluents.
   • Operational Rules:
     • Reconstituted and active vials must be rested in the plastic foam pad / sponge inserted at the top of the carrier, never placed directly on ice or allowed to fall to the bottom.
     • The carrier lid must be kept firmly sealed between withdrawals to prevent hot air entry.
     • The carrier must be positioned in complete shade, away from direct sunlight, open windows, stoves, or heaters.

1. Cold Chain Definition & Operational Temperatures at PHC Level:
   • Definition: A continuous, uninterrupted system of storing, transporting, and distributing potent vaccines at designated, controlled temperatures from the point of manufacture to the point of clinical administration.
   • Storage Temperatures at PHC/CHC level:
     • Freeze-sensitive vaccines (Pentavalent, DTwP/Tdap, Td, Hepatitis B, PCV, IPV, Rotavirus): Stored strictly at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$.
     • Live viral vaccines (bOPV, MR/MMR, JE, BCG): Maintained at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$ at PHC/CHC level (while regional/national stores store bOPV at $-15^\circ\text{C}\text{ to }-25^\circ\text{C}$, PHCs store all UIP vaccines uniformly at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$ in the ILR).
2. ILR vs Deep Freezer Functions at PHC:
   • Ice-Lined Refrigerator (ILR): Dedicated strictly for storing all vaccines and diluents at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$. Contains internal lining of water/ice pipes that maintain temperature for up to $20\text{ to }72\text{ hours}$ during power outages.
   • Deep Freezer (DF): Operates at $-15^\circ\text{C}\text{ to }-25^\circ\text{C}$. Dedicated primarily to freezing and preparing water ice packs for outreach carriers. Freeze-sensitive vaccines must never be kept in the deep freezer.
3. Spatial Distribution of Vaccines inside an ILR:
   • Bottom Zone / Floor: Coldest area (temperatures approach $0^\circ\text{C}$ or sub-zero).
     • Live, heat-sensitive vaccines: bOPV, BCG, and Measles/MR/MMR.
   • Upper Zone / Top Baskets: Warmer area (maintains $+4^\circ\text{C}\text{ to }+8^\circ\text{C}$).
     • Freeze-sensitive vaccines: Pentavalent (DTwP-HepB-Hib), DTwP, Td, TT, Hepatitis B, IPV, PCV, and Rotavirus.
   • General ILR Rules: Keep vaccines in designated wire baskets; maintain $1\text{ to }2\,\text{cm}$ space between individual boxes for airflow; never keep vaccines on the bare bottom floor; diluents placed alongside corresponding vaccines at least 24 hours prior to use.
4. Shake Test Protocol and Interpretation:
   • Indication: Suspected accidental freezing of adsorbed vaccines containing aluminum adjuvants (Pentavalent, DTwP, DTaP, Td, Hep B, PCV).
   • Procedure:
     1. Select a suspected frozen vial ("Test Vial").
     2. Select a control vial from the same manufacturer, batch, and lot. Deliberately freeze it solid at $-20^\circ\text{C}$ overnight, thaw completely, and label it ("Frozen Control").
     3. Vigorously shake both vials simultaneously for 10–15 seconds.
     4. Place both vials side-by-side on a flat surface against a light background and observe sedimentation without moving them at 1, 5, 15, and 30 minutes.
   • Interpretation:
     • Pass (Not frozen): The test vial remains cloudy/turbid and precipitates significantly slower than the control vial; at 15–30 minutes, sediment forms faster in the frozen control, leaving clear supernatant.
     • Fail (Frozen & Damaged): Sedimentation rate in the test vial is equal to or faster than that of the frozen control, forming a granular precipitate with a clear supernatant within 15 minutes.
   • Action: If failed, the batch has irreversible aluminum adjuvant crystal aggregation; discard the entire affected lot immediately.

1. Descending Order of Heat Sensitivity:
   $$\text{BCG (reconstituted)} > \text{bOPV} > \text{MMR} > \text{DTwP} > \text{BCG (unreconstituted)} > \text{Td} > \text{Hepatitis B}$$
   (Reconstituted live vaccines lose potency rapidly at room temperature within hours; Hepatitis B is one of the most heat-stable liquid vaccines).
2. Descending Order of Freeze Sensitivity:
   $$\text{Hepatitis B} > \text{DTwP} > \text{Td} > \text{TT} > \text{MMR} > \text{BCG}$$
   (Hepatitis B is exquisitely freeze-sensitive, suffering lattice disruption at $-0.5^\circ\text{C}$; freeze-dried BCG and MMR tolerate sub-zero temperatures well).
3. Catch-up Schedule for an Unimmunized 10-Year-Old Adolescent:
   • Visit 1 (Day 0 / Immediate):
     • Tdap ($0.5\,\text{mL}$ IM) as the primary priming dose.
     • bOPV / IPV (IPV $0.5\,\text{mL}$ IM preferred; or fractional intradermal IPV per UIP).
     • Hepatitis B (Dose 1: $10\text{ to }20\,\mu\text{g}$ IM).
     • MMR (Dose 1: $0.5\,\text{mL}$ SC).
     • Human Papillomavirus (HPV): Single dose or 2-dose series (Dose 1: $0.5\,\text{mL}$ IM; 9-valent or bivalent/quadrivalent).
     • Typhoid Conjugate Vaccine (TCV): $0.5\,\text{mL}$ IM single dose.
     • Hepatitis A: Dose 1 ($0.5\,\text{mL}$ IM).
   • Visit 2 (1 month / 4 weeks after Visit 1):
     • Hepatitis B (Dose 2: IM).
     • MMR (Dose 2: $0.5\,\text{mL}$ SC).
     • Varicella (Dose 1: $0.5\,\text{mL}$ SC; 2 doses separated by $\ge 4\text{ to }8$ weeks).
     • Td (Dose 2: $0.5\,\text{mL}$ IM, to complete primary tetanus-diphtheria series).
   • Visit 3 (2 months after Visit 1 / 4 weeks after Visit 2):
     • Varicella (Dose 2: $0.5\,\text{mL}$ SC).
   • Visit 4 (6 months after Visit 1):
     • Hepatitis B (Dose 3: IM).
     • Td (Dose 3: $0.5\,\text{mL}$ IM, completing the 3-dose Td/Tdap primary course).
     • Hepatitis A (Dose 2: 6 months after dose 1 if using inactivated 2-dose vaccine).
     • HPV (Dose 2: if following standard 2-dose schedule at 0 and 6 months).
   • Long-term Maintenance: Td booster every 10 years throughout adulthood.
4. Biophysical Mechanism of Freezing Damage:
   • Freezing causes water to form expanding ice crystals within the vaccine suspension.
   • These ice crystals compress and physically disrupt the hydrated aluminum hydroxide or aluminum phosphate colloidal gel lattice.
   • This forces the adjuvant particles to aggregate irreversibly into large, dense, insoluble crystalline conglomerates.
   • The adsorbed protein antigens dissociate and denature, stripping the vaccine of its depot-forming property and antigen-presenting capability, severely diminishing immune response and causing local sterile granulomas/abscesses.

1. Maximum In-Use Stability Following Reconstitution ($+2^\circ\text{C}\text{ to }+8^\circ\text{C}$):
   • Varicella vaccine: 30 minutes (extremely labile; manufacturer guidelines mandate discard if not used within 30 minutes).
   • BCG vaccine: 4 hours (strict 4-hour limit under UIP/WHO guidelines).
   • Measles / MR / MMR vaccine: 4 hours (discard within 4 hours; maximum permissible limit under strict cold chain is 6 hours; UIP standard is 4 hours).
   • Yellow Fever vaccine: 1 hour (must be discarded after 1 hour).
   • Meningococcal Conjugate Vaccine (MCV): 30 minutes (or within time specified by manufacturer, typically $\le 30$ minutes to 1 hour).
   • DTaP-Hib / Lyophilized Hib combination: 30 minutes (use immediately; discard within 30 minutes).
2. Diluent Specifications and Substitution Hazard:
   • Diluents:
     • BCG: $0.9\%\text{ Sodium Chloride}$ (Normal Saline) Injection.
     • Measles / MR / MMR: Sterile Water for Injection (SWFI).
   • Hazard of using SWFI for BCG:
     • SWFI is hypotonic compared to human extracellular fluid.
     • Reconstituting BCG in SWFI creates a severely hypotonic solution that leads to endosmotic swelling and osmotic lysis of the attenuated M. bovis bacilli, drastically reducing viable colony-forming units (CFUs).
     • Intradermal injection of hypotonic solution causes severe localized pain, severe tissue necrosis, and sterile local cold abscess formation.
3. Toxic Complication of Stale Reconstituted Measles Vaccine:
   • Syndrome: Toxic Shock Syndrome (TSS) (characterized by acute high fever, vomiting, watery diarrhea, diffuse erythroderma, rapid hypotensive collapse, and multi-organ failure within hours of administration).
   • Etiologic Pathogen: Staphylococcus aureus. Reconstituted measles vaccine lacks preservatives; warm storage allows rapid bacterial multiplication and production of Staphylococcal Toxic Shock Syndrome Toxin-1 (TSST-1) / enterotoxins acting as superantigens.
4. Open Vial Policy Applicability:
   • Ineligible: Reconstituted live attenuated vaccines (BCG, Measles/MR/MMR, Varicella, Yellow Fever, JE) are strictly excluded from the Open Vial Policy.
   • They must be discarded at the end of the immunization session or within 4 hours of reconstitution (whichever is earlier) and can never be stored for subsequent clinic sessions. Multi-dose liquid formulations of DTwP, Hep B, OPV, IPV, and Td are eligible for retention up to 28 days provided Open Vial Policy criteria are satisfied.

1. National Vitamin A Prophylaxis Schedule:

   • Total number of doses: 9 doses.
   • Schedule:
     • First dose: Administered at 9 completed months along with the 1st dose of Measles-Rubella (MR) vaccine.
     • Subsequent doses (2nd to 9th dose): Administered every 6 months thereafter (at 16–18 months with the DPT booster, and subsequently at 24, 30, 36, 42, 48, 54, and 60 months) during biannual rounds (National Deworming Day / Biannual Vitamin A Rounds).
   • Age of final dose: 5 years (60 months) of age.

2. Dosing and Storage Guidelines:

   • Age-specific prophylactic dosing:
     • Infants aged 6 to 11 completed months: 100,000 IU (1 lakh IU) orally, equivalent to 1 mL of standard oral suspension (using the provided 1-mL dispenser spoon).
     • Children aged 12 to 59 months: 200,000 IU (2 lakh IU) orally, equivalent to 2 mL of standard oral suspension (two full spoons).
   • Storage guidelines:
     • Keep bottles tightly sealed and strictly protected from direct sunlight (Vitamin A is photo-sensitive and degrades rapidly under UV exposure).
     • Store in an opaque, cool, and dry location (preferably below 25°C to 30°C; does not require cold-chain refrigeration, but must not freeze).
     • Unopened bottles can be used up to the stamped manufacturer expiry date.
     • Once opened, record the opening date on the label; the bottle should be utilized within 6 to 8 weeks and discarded if discolored, precipitated, or expired.

3. Therapeutic Vitamin A Protocol for Acute Measles:

   • Patient Age: 9 months (infant aged 6–11 months).
   • Standard Therapeutic Dosing:
     • Dose 1: 100,000 IU (1 lakh IU orally) given immediately upon diagnosis (Day 1).
     • Dose 2: 100,000 IU (1 lakh IU orally) given the following day (Day 2).
   • Indications for a Third Dose:
     • Administer a 3rd dose of 100,000 IU orally at 2 to 4 weeks (14–28 days) post-diagnosis if the child displays:
       • Clinical ocular signs of Vitamin A deficiency (e.g., night blindness, Bitot's spots, corneal xerosis/ulceration).
       • Severe acute malnutrition (SAM) or kwashiorkor.
       • Underlying chronic malabsorption or prolonged unremitting diarrhea.

4. WHO Classification of Xerophthalmia:

   • XN: Night blindness
   • X1A: Conjunctival xerosis
   • X1B: Bitot's spots
   • X2: Corneal xerosis
   • X3A: Corneal ulceration / keratomalacia involving $< 1/3$ of the corneal surface
   • X3B: Corneal ulceration / keratomalacia involving $\ge 1/3$ of the corneal surface
   • XS: Corneal scars (healed sequelae)
   • XF: Xerophthalmic fundus (structural retinal changes)